KPV is a kpv research peptide of growing interest within the published literature. The tripeptide Lys-Pro-Val has emerged as an area of scientific investigation due to its structural relationship to alpha-melanocyte-stimulating hormone (α-MSH) and the biological activities investigated in in vitro cell culture systems and rodent model research. This overview summarizes the published research landscape and proposed mechanisms as documented in peer-reviewed literature. All content is provided for scientific reference purposes and relates exclusively to laboratory research.

What Is KPV?

KPV (Lys-Pro-Val) is a tripeptide corresponding to the C-terminal sequence of α-melanocyte-stimulating hormone (α-MSH). Alpha-MSH is a 13-amino acid neuropeptide derived from the proopiomelanocortin (POMC) precursor protein, with the full sequence Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. The C-terminal tripeptide KPV (positions 11–13) has been studied independently in research literature as a minimal active sequence derived from the parent peptide.

KPV has a molecular weight of approximately 340.4 Da. Its small size distinguishes it from many other research peptides and has been noted in published studies as a structural feature relevant to its physicochemical properties and potential experimental applications. The tripeptide’s relationship to the melanocortin system — specifically the melanocortin 1 receptor (MC1R) — has been a focus of mechanistic investigation, with some published research proposing that KPV may interact with biological pathways through mechanisms that are partly independent of canonical MC1R signaling.

Published Research Landscape

Published research on KPV has appeared in Peptides, Journal of Pharmacology and Experimental Therapeutics, Inflammatory Bowel Diseases, and related journals. The research has been concentrated in the following areas:

• NF-κB pathway research in cell culture: Multiple published in vitro studies have investigated KPV in the context of NF-κB signaling, a transcription factor pathway of broad relevance to inflammation-related research. Cell culture studies have documented associations between KPV exposure and NF-κB pathway parameters in intestinal epithelial cell lines and macrophage cell culture systems under defined experimental conditions. These findings are in vitro only.
• Gut mucosal biology in rodent models: Published rodent model research has investigated KPV in the context of gut mucosal biology, employing experimental colitis models to examine histological and biochemical parameters. Studies in this area, including work published in Inflammatory Bowel Diseases and related journals, have documented changes in inflammatory marker expression in rodent mucosal tissue following KPV administration. These are animal model findings only — they do not establish KPV as a treatment or preventive agent for any gastrointestinal condition in humans.
• Skin and cutaneous biology in cell culture: Research published in Peptides and related journals has investigated KPV in cell culture models relevant to cutaneous biology, including keratinocyte cultures. Published studies have documented associations between KPV and inflammatory pathway parameters in skin-relevant cell culture systems. No clinical claims are made or implied by this research.
• Oral and mucosal delivery research: A subset of published research has investigated KPV in formulation contexts examining mucosal delivery kinetics, including encapsulated and nanoparticle delivery systems, as methodological investigations into delivery route optimization for peptide research applications.

Proposed Mechanism of Action

Based on the published in vitro and animal model research, the following mechanisms have been proposed to account for the biological activities observed in KPV studies. These remain proposed mechanisms from preclinical research:

• NF-κB inhibition in vitro: Published cell culture studies have documented associations between KPV exposure and reduced NF-κB nuclear translocation and downstream target gene expression in intestinal epithelial and macrophage cell lines. The molecular basis of this interaction has been investigated in a subset of publications, with proposed interactions at intracellular signaling steps proximal to IκB kinase (IKK) activity.
• MC1R-independent signaling: Some published research has investigated whether KPV’s observed activities in cell culture are fully attributable to canonical melanocortin 1 receptor (MC1R) engagement, noting that certain in vitro effects have been documented in cell lines with low or absent MC1R expression. The mechanistic basis of potential MC1R-independent activity is not fully resolved in the published literature.
• Cytokine modulation in culture systems: Published cell culture studies have documented associations between KPV exposure and secretion profiles of pro-inflammatory cytokines, including TNF-α and IL-1β, in stimulated macrophage cultures. These are in vitro findings.
• Epithelial barrier parameters in culture: Some published research has investigated KPV in intestinal epithelial monolayer culture systems, examining parameters related to barrier function under inflammatory challenge conditions.

It is critical to note that all proposed mechanisms are derived from in vitro cell culture research and rodent model studies. The translation of these findings to human biology has not been established, and KPV is not approved or indicated for the management of any human health condition.

Supply Format for Research

Struck Bio Labs supplies KPV in two formats for research applications:

• KPV 10mg vial — lyophilised powder, supplied for laboratory reconstitution and research use
• KPV Capsules 500mcg — encapsulated format for research protocols investigating oral or mucosal delivery models

All products are accompanied by COA documentation confirming identity and purity, and are supplied for laboratory research use only.

Frequently Asked Questions

What is the structural relationship between KPV and alpha-MSH?

KPV (Lys-Pro-Val) corresponds to residues 11–13 at the C-terminus of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino acid neuropeptide derived from the POMC precursor. KPV has been studied as a minimal sequence fragment in an effort to understand which structural elements of the parent peptide are associated with the biological activities documented in α-MSH research.

What cell lines have been used in published KPV in vitro research?

Published KPV research has employed intestinal epithelial cell lines (including Caco-2 and HT-29), macrophage cell lines (including RAW 264.7), and primary keratinocyte cultures, among others. Experimental conditions, stimulation protocols, and readout parameters vary across publications — researchers are advised to consult the methodology sections of the primary literature before designing analogous experiments.

What rodent models have been used in published KPV gut research?

Published KPV mucosal research has employed experimental colitis models in mice and rats, including dextran sodium sulfate (DSS)-induced colitis and trinitrobenzene sulfonic acid (TNBS) models. These are standard preclinical research tools used broadly in mucosal biology research and represent animal model data only.

Has KPV been studied in skin-relevant cell culture systems?

Yes — published research, including studies in Peptides journal, has investigated KPV in keratinocyte and skin-relevant cell culture systems, examining associations with inflammatory pathway parameters under defined stimulation conditions. These are in vitro findings from cell culture research only and do not constitute evidence of efficacy for any dermatological condition.

What is the significance of the encapsulated format for KPV research?

The encapsulated format is relevant to research protocols investigating oral or mucosal delivery models for small peptides. Published research on KPV has included investigations of nanoparticle and encapsulated delivery systems as methodological approaches to oral peptide delivery in animal model research. The capsule format from Struck Bio Labs is supplied for laboratory research use only.

Does KPV require special reconstitution or handling for research use?

Lyophilised KPV vials are typically reconstituted in sterile or bacteriostatic water for research use. Due to its small molecular size and high solubility, KPV is generally considered straightforward to reconstitute, but researchers should prepare working solutions per their experimental protocol and store per COA specifications. As with all lyophilised peptides, minimize freeze-thaw cycles and consult lot-specific stability data from the accompanying COA.

Further Reading: BPC-157 Research • KPV Research • Storage Guide • Browse Healing Research Peptides • Disclaimer